Commodity Chemicals

CHINA RISUN GP

China Xuyang's Domestic First Commercial Liquid Hydrogen Project Goes Online, Filling Industry Gap

China Xuyang Group Launches 50,000 Ton/Year HMDA Plant

China Xuyang Group Acquires 14.50% Shares of Tianjin Binhai Energy Development Co., Ltd.

China Xuyang Group Releases 2025 ESG Report, Emphasizes Hydrogen Business Expansion

China Xuyang Group to Hold Annual General Meeting on May 29th

Xuyang Group and Hangyang Group Sign Strategic Cooperation Agreement in Hydrogen Energy

Xuyang Group Achieves Dual Breakthroughs in Scale and Profitability in Operation Management Services

Coking Coal Industry's Second Round of Price Increases Fully Implemented

China Xuyang Group Capacity Expansion and Coke Industry Market Analysis

China Xuyang Group Sees Net Profit Growth of 37.7% in 2025

Global Prosperity Maintains Buy Rating for China Xuyang Group

China Xuyang Group Completes Catalyst Filling for Caprolactam-to-Adipic Acid Unit

China 旭 Yang Group Reports Net Profit Growth of 37.7% to 135 Million Yuan in 2025

CHINA RISUN GP released FY2025 9 Months earnings on March 29, 2026 (BJT), actual revenue HKD 32.49 B, actual EPS HKD 0.0106

CHINA RISUN GP released FY2025 Q3 earnings on March 29, 2026 (BJT), with actual revenue of HKD 10.24 B and EPS of HKD 0.0034

China Xuyang Group Reports 2025 Profit Growth and New Plant Commissioning

China Xuyang Group reports a 37.7% increase in net profit to 135 million yuan for the fiscal year 2025

CHINA RISUN GP released FY2025 Q4 earnings on March 29 During-Market (BJT), actual revenue HKD 10.42 B, actual EPS HKD 0.0035

CHINA RISUN GP released FY2025 earnings on March 29 During-Market (BJT), actual revenue HKD 42.94 B (forecast HKD 48.44 B), actual EPS HKD 0.0142 (forecast HKD 0.022)

CHINA RISUN GP to Release FY2025 Earnings on March 27 During-Market (BJT), Forecast Revenue HKD 49.7 B, EPS HKD 0.022

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

Ordinary dividend (cash)

Ex Date: 2026.06.08, Cash dividend 0.0022 HKD

CHINA RISUN GP (1907.HK) 2024 Annual Performance Release Conference

01907

China Risun Group has successfully commenced production at its new 50,000-ton/year hexamethylenediamine (HMDA) plant, breaking foreign monopolies on adiponitrile technology. This innovation allows direct production of HMDA from caprolactam, enhancing China's nylon industry. The project, recognized as a key engineering initiative by Shandong Province, showcases Risun's R&D capabilities and industrial synergy, significantly reducing production costs and improving efficiency. The company aims to expand its nylon-related product offerings and strengthen its position in the high-end chemicals market.

Asian Corporate Newswire

Breaking Through 'Chokepoint' Technology: China Risun's Hexamethylenediamine Plant Commenced Production

02659

02635

00819

02591

01858

06869

02442

02650

00631

BAO PHARMA-B(02659) fell 65.55%, with a trading turnover 785.1 Million HKD, and a year-to-date fell 66.7%. NUOBIKAN(02635) fell 31.2%, with a trading turnover 281.8 Million HKD, and a year-to-date fell 47.2%. TIANNENG POWER(00819) fell 27.25%, with a trading turnover 720.0 Million HKD, and a year-to-date fell 19%.

Top Gainers&Losers

BAO PHARMA-B

NUOBIKAN

TIANNENG POWER

INNOGEN-B

CHUNLI MEDICAL

YOFC

EASY SMART GP

ZHIDA TECH

SANY INT'L

Top 10 HK Stock Losers (4.30)

Today, CHINA RISUN GP had a trading volume of approximately HKD 155 million, which is relatively active in recent trading. Bullish signals are beginning to emerge on the daily MACD level. The appearance of this technical pattern usually indicates that the bearish forces during the previous adjustment process are gradually weakening, and the selling pressure at the current price level has eased. In terms of price movement, the stock price of RISUN GP has recently fluctuated repeatedly in the low range, with trading volume showing a moderate recovery, indicating that some funds are gradually accumulating shares at low levels. On the news front, the coking industry is currently in a period of capacity adjustment and price fluctuations, with signs of stabilization in coke prices after a previous decline, providing marginal support for the profit expectations of coking enterprises. On the macro level, domestic policies to stabilize growth continue to be effective, with infrastructure and manufacturing investment maintaining resilience. Although downstream steel demand has not significantly rebounded, it has not further deteriorated. In addition, the overall market sentiment in the Hong Kong stock market was relatively warm today, with both the Hang Seng Index and the National Enterprises Index recording gains, providing a certain bullish atmosphere for small and medium-sized market capitalization targets. From a technical perspective, the current stock price of CHINA RISUN GP is near the lower edge of the recent range, and the emergence of bullish signals at low levels has a certain "bottom testing" implication. However, the overall trading volume of HKD 155 million is relatively small, and the reliability of the signals still needs to be confirmed by subsequent volume increases. If there can be a continuous moderate increase in volume over the next few trading days, the probability of a bottom formation will significantly increase. Overall, bullish signals are beginning to appear in the low range, but the weak volume limits the strength of the signals

Technical Forecast

Hang Seng Index

Hang Seng China Enterprises Index

Pre-market trend | CHINA RISUN GP (1907.HK) low-level bullish signals emerged on 4/29, is capital starting to pay attention?

02359

01528

06127

09959

00326

01888

02652

01277

01898

WUXI APPTEC(02359) rose 13.57%, with a trading turnover 3.0 Billion HKD, and a year-to-date rose 45%. RS MACALLINE(01528) rose 11.11%, with a trading turnover 129.4 Million HKD, and a year-to-date rose 23%. JOINN(06127) rose 9.26%, with a trading turnover 216.2 Million HKD, and a year-to-date rose 14.6%.

WUXI APPTEC

RS MACALLINE

JOINN

LINKLOGIS-W

CHINA STAR ENT

KB LAMINATES

CF PHARMTECH

KINETIC DEV

CHINA COAL

Top 10 HK Stock Gainers (4.28)

CGS International has maintained a Buy rating on China Risun Group Ltd. with a price target of HK$4.20, while the shares closed at HK$3.00. The overall analyst consensus for the company is a Strong Buy, with an average price target of €0.43.

Tip Ranks

CGS International Remains a Buy on China Risun Group Ltd. (45Y)

In a report released yesterday, from Global Prosperity maintained a Buy rating on China Risun Group Ltd., with a price target of HK$3.80.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The word on The Street in general, suggests a Moderate Buy analyst consensus rating for China Risun Group Ltd. with a €0.42 average price target.

Global Prosperity Sticks to Its Buy Rating for China Risun Group Ltd. (45Y)

China Risun Group Limited reported a 37.7% increase in net profit for 2025, reaching approximately RMB 135 million, despite a 17.4% decline in revenue to RMB 39.286 billion due to falling prices in the coke and chemical markets. The company improved operational efficiency through cost control, with a gross profit margin increase to 7.8%. The Group also advanced in hydrogen energy and high-end chemicals, launching new projects and expanding its market share. A final dividend of RMB 0.19 cents per share was proposed, reflecting a commitment to shareholder returns.

China RisunReports Strong 37.7% Net Profit Surge in 2025 Amid Industry Challenges

China Risun Group (SEHK:1907) reported FY 2025 H1 revenue of C¥20.5b and basic EPS of C¥0.0066, with a net profit margin of 0.1%, up from 0.04% last year. Despite a 188.1% earnings growth over the last year, the company faces volatility with earnings swinging from a loss of C¥91.7m to a profit of C¥28.6m. The shares trade at a low P/S ratio of 0.3x, with a DCF fair value of HK$18.71 compared to the current price of HK$3.44, indicating potential mispricing but also financing risks due to weak interest coverage.

Simplywall

China Risun Group SEHK 1907 Thin 0.1% Margin Recovery Tests Bullish Earnings Narratives

China Risun Lifts Profit on Higher Output Despite Revenue Decline in 2025

China Risun Lifts Profit on Higher Output Despite Revenue Decline in 2025

CHINA RISUN GP(01907.HK)

Breaking Through 'Chokepoint' Technology: China Risun's Hexamethylenediamine Plant Commenced Production

Top 10 HK Stock Losers (4.30)

Pre-market trend | CHINA RISUN GP (1907.HK) low-level bullish signals emerged on 4/29, is capital starting to pay attention?

Top 10 HK Stock Gainers (4.28)

CGS International Remains a Buy on China Risun Group Ltd. (45Y)

Global Prosperity Sticks to Its Buy Rating for China Risun Group Ltd. (45Y)

China RisunReports Strong 37.7% Net Profit Surge in 2025 Amid Industry Challenges

China Risun Group SEHK 1907 Thin 0.1% Margin Recovery Tests Bullish Earnings Narratives

China Risun Lifts Profit on Higher Output Despite Revenue Decline in 2025

Trending